Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of NantKwest Inc (NASDAQ: NK) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of NantKwest Inc (NASDAQ: NK) concerning whether a series of statements by NantKwest Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 11, 2016, NantKwest revealed that its financial statements for the quarters ended June 30, 2015 and September 30, 2015 should no longer be relied upon and that the Company intends to restate them. The errors in the financial statements were mainly due to certain stock-based awards to NantKwest’s Chief Executive Officer and Executive Chairman and build-to-suit lease accounting related to one of its research and development and Good Manufacturing Practices facilities.

On this news, NASDAQ: NK shares declined as much as $0.86, or 10.18%, to $7.59 during intraday trading on March 11, 2016.

Based in Cardiff-by-the-Sea, CA, and founded in 2002 NantKwest Inc is a biotechnology company, developing immunotherapeutic agents for various clinical conditions.

If you purchased shares of NantKwest Inc (NASDAQ: NK) on or before March 11, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185